The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:2071-2072 November 20, 2003 Number 21
NextNext

G-CSF Priming in Acute Myelogenous Leukemia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Löwenberg, B.
-PubMed Citation
To the Editor: The study by Löwenberg et al. (Aug. 21 issue)1 suggests that the possible priming effect of the administration of granulocyte colony-stimulating factor (G-CSF) concurrently with remission-induction therapy may improve the outcome of some cases of newly diagnosed leukemia. However, the priming effect of G-CSF was not demonstrated in an intention-to-treat analysis, only in a subgroup analysis. In addition to the small benefit of this treatment, if it has any at all, its safety remains questionable. During an early postinduction phase, the G-CSF group had a significantly higher mortality rate (55 of 321 patients died) than the group . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.